FDA Update Warns of Mental Health, Hypoglycemia Risks with Fluoroquinolone

Jennifer Barrett, Associate Editor
Published Online: Wednesday, July 11th, 2018
Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects, and blood sugar disturbances, according to a press release. The FDA stated that all fluoroquinolone antibiotics already included a range of mental health adverse effects described in the Warnings and Precautions section of the drug labeling, but have differed by individual drug.
Now, the FDA is requiring mental health adverse effects to be listed separately from the other central nervous system adverse effects, and be consistent across the labeling of all fluoroquinolone antibiotics. The mental health adverse effects to be included in the updated labeling are disturbances in attention, disorientation, agitation, nervousness, memory impairment, and delirium.
The updates apply to the drug labels and the patient medication guides for the entire class of fluoroquinolones, which affect only the fluoroquinolone formulations taken by mouth or given by injection.
According to an FDA drug safety communication, the new label changes “will make the mental health side effects more prominent and more consistent across the systemic fluoroquinolone drug class.” FDA-approved fluoroquinolones include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin, gemifloxacin (Factive), and delafloxacin (Baxdela).
Additionally, the labeling must also be updated to include risks related to hypoglycemia. Based on a previous review that found instances of hypoglycemic coma in users of fluoroquinolones, the FDA is requiring that the Blood Glucose Disturbances subsection of the labeling be updated to explicitly reflect the potential risk of coma with hypoglycemia.
The FDA urges health care professionals to be aware of the potential risk of hypoglycemia sometimes resulting in coma, which can occur in elderly patients and those with diabetes taking an oral hypoglycemic medicine or insulin.

This article originally appeared at SpecialtyPharmacyTimes.com.

FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions [news release]. FDA’s website. http://www.pharmacytimes.com/link/194. Accessed July 10, 2018.
FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes [safety announcement]. FDA’s website. https://www.fda.gov/Drugs/DrugSafety/ucm611032.htm. Accessed July 10, 2018.

Current Issue

The Educated Patient

Jennifer L. Hofmann, MS, PA-C
Providing them with advice can improve control of the disease and reduce hospitalizations, morbidity, and unscheduled health care visits.
Emily C. Hayes, PharmD Candidate
Colds, coughs, and a relentless influx of sick patients in retail health clinics keep the health care providers who work there very busy.
Kristen Marjama, DNP, APRN-BC
Although the rate of foot and leg amputation has greatly declined over the past 2 decades, increasing awareness for macrovascular and microvascular complications of diabetes is essential because diabetes is the leading cause of lower-limb amputations in the United States.
Kristen Marjama, DNP, FNP-BC
Gluten proteins found in barley, rye, and wheat trigger systemic injury primarily to the small intestine, but they can also affect the joints, liver, skin, uterus, and other organs.
$vacMongoViewPlus$ $vAR$
Contemporary Clinic
MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Specialty Pharmacy Times
Targeted Oncology
About Us
Contact Us
Terms & Conditions
Pharmacy Healthcare & Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-257-0701

Copyright Contemporary Clinic 2018
Pharmacy Healthcare & Communications, LLC. All Rights Reserved.